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Background: Mutations in LYST, a gene encoding a putative lysosomal trafficking protein, cause Chédiak-Higashi
syndrome (CHS), an autosomal recessive disorder typically characterized by infantile-onset hemophagocytic
syndrome and immunodeficiency, and oculocutaneous albinism. A small number of reports of rare, attenuated
forms of CHS exist, with affected individuals exhibiting progressive neurodegenerative disease beginning in early
adulthood with cognitive decline, parkinsonism, features of spinocerebellar degeneration, and peripheral
neuropathy, as well as subtle pigmentary abnormalities and subclinical or absent immune dysfunction.
Methods: In a consanguineous Pakistani kindred with clinical phenotypes consistent with attenuated CHS, we
performed SNP array-based homozygosity mapping and whole gene sequencing of LYST.
Results: We identified three individuals homozygous for a novel six base pair in-frame deletion in LYST
(c.9827_9832ATACAA), predicting the loss of asparagine and threonine residues from the LYST transcript
(p.Asn3276_Thr3277del), and segregating with the phenotype in this family.
Conclusions: We further characterize the neurologic features of the attenuated form of CHS, and discuss
pathophysiologic mechanisms underlying the neurodegenerative components of CHS. Attenuated CHS is
phenotypically heterogenous and should be considered when young adults develop neurodegenerative disease
and have pigmentary abnormalities. We briefly discuss surveillance and management of patients with CHS-related
neurodegeneration.
Keywords: Chédiak-Higashi syndrome, LYST, Lysosomal, Amyloid, Oxidative stress, Parkinsonism, Neurodegenerative
diseaseBackground
Mutations in LYST result in Chédiak-Higashi syndrome
(CHS; MIM 214500), a rare autosomal recessive disorder
typically characterized by immune dysfunction in early
childhood, partial oculocutaneous albinism and other
pigmentary abnormalities, and, in survivors of the acce-
lerated phase of immune deterioration, late-onset neuro-
logic dysfunction. Progressive neurodegenerative disease* Correspondence: james.weisfeld-adams@mssm.edu
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distribution, and reproduction in any mediumwith subtle pigmentary abnormalities and absent or sub-
clinical immunologic abnormalities are the hallmarks of
the attenuated form of CHS [1-3]. This form of CHS has
been estimated to account for 10–15% of all CHS pa-
tients [4], but may be underdiagnosed. Neurologic mani-
festations appear to be variable, but frequently include
peripheral neuropathy, intellectual decline, parkinson-
ism, ataxia, and white matter abnormalities [4-8]. Geno-
typing of individuals with these phenotypes has, to date,
identified only four causative LYST genotypes, all of
them missense mutations; infantile-onset disease is asso-
ciated with null LYST alleles. Here we report a largeCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mozygous for a novel deletion in exon 43 of LYST and




For participation and publication of this material, written
consent was obtained from all participants in accordance
with the policies and procedures of the institutional ethics
committee of the Mount Sinai School of Medicine, and in
compliance with the Helsinki Declaration. In the three af-
fected patients (III:9, female, 43 years; III-12, male, 38 years;
III-14, male, 33 years; see Figure 1), the diagnosis was
established by medical history and detailed clinical evalu-
ation. Neurologic testing encompassed standard testing of
gait, balance, and coordination, magnetic resonance im-
aging (MRI) of the brain and, in the case of III-14, of the
spine, as well as electromyography (EMG) and nerve con-
duction studies. Ophthalmologic examination consisted of
dilated funduscopy, Goldmann perimetry and standard
tests of color and contrast sensitivity. Immunologic testing
employed natural killer (NK) cell functional assays and
immunoglobulin testing. Peripheral blood smears were
visualized using Wright-Giemsa staining and oil im-
mersion. Hair shafts were analyzed using standard light
microscopy. Skin biopsy samples were analyzed using
standard hematoxylin and eosin and Congo Red staining,
and immunohistochemistry.
Genetic diagnosis was confirmed with sequencing of
the entire coding region of LYST in the proband. Blood
samples were obtained for DNA extraction, and genomic
DNA was isolated using standard protocols. Samples for
each patient were received at Prevention Genetics as
DNA. Exonic and immediate flanking DNA of the LYST
gene was amplified using standard PCR conditions and
KAPATaq HotStart enzyme (Kapa Biosystems, Woburn,
MA, USA). PCR primers were tailed with m13 forward
and reverse priming sequences. PCR products were se-
quenced in both forward and reverse directions using
m13 primers and BigDye dideoxynucleotide terminators
(Applied Bio, Carlsbad, CA, USA). Patient DNA se-Figure 1 Family pedigree. Shaded shapes indicate affected individuals. Th
to their first cousins. The spouses of Brother 2 (III:14), and the two unaffectquences were analyzed using SeqScape software (v2.5,
Applied Bio, Carlsbad, CA, USA).
Results
Clinical evaluation
Three affected siblings were part of a large consanguin-
eous family of Pakistani extraction (Figure 1). The pro-
band (III:9), was 40 years old at the time of initial
evaluation in Medical Genetics. She had a 9 year history
of progressive leg weakness with cognitive impairment,
cerebellar ataxia with hypermetric saccades, and parkin-
sonian features including bradykinesia, masked facies, and
hypophonia. In childhood, she had a history of learning
difficulties and attention-deficit behaviors without hyper-
activity. She had a long history of arthralgias and limb
contractures. She had generalized hyperpigmentation,
noted in infancy and followed by the appearance of wide-
spread hypopigmented macules persisting into adulthood.
She had a history of multiple dental infections in child-
hood and severe periodontitis at the age of 36 years, but
no other history suggestive of immunodeficiency. There
was no history of bleeding. Physical examination revealed
generalized hyperpigmentation with widespread small
hypopigmented macules and patches distributed over her
entire body. She had age-appropriate hair graying. She
was wheelchair-bound, and exhibited bradykinesia, hy-
pomimia, hypophonia, pseudobulbar affect, cerebellar
ataxia, ocular dysmetria, spasticity and motor weakness
with near plegia in the lower limbs. Deep tendon reflexes
were reduced in the lower limbs but hyperactive in the
upper limbs. Neuropsychologic testing revealed a mild de-
mentia syndrome. Neuro-ophthalmologic evaluation dem-
onstrated decreased color vision and contrast sensitivity.
There was myopic astigmatism bilaterally. There was se-
vere optic nerve pallor and peripheral patchy retinal
hypopigmentation bilaterally. Goldmann perimetry re-
vealed central loss. Parkinsonian symptoms did not im-
prove with levodopa-carbidopa, and she experienced
lightheadedness.
Two younger brothers had similar cutaneous appea-
rances and extracutaneous symptoms to their sister
(Figure 2A and B). Neither was reported to have ae proband and Brother 1 (III:9 and III:12, respectively) are both married
ed brothers (III:10 and III:16) are from families unrelated to this sibship.
Figure 2 (A) and (B) Macroscopic skin appearances of Brother 2 at age 33 years. He reported hair graying dating from adolescence. He
recalled abnormal skin pigmentation appearing in early adulthood; this is in contrast to his sister, whose parents report had developed
pigmentary abnormalities in early childhood. Her skin changed in appearance over time, initially exhibiting generalized hyperpigmentation, but
with development of hypopigmented macules in early adulthood. (C) Goldmann visual fields of Brother 1 at aged 38 years. Despite significant
central and peripheral field loss, he reported no subjective deficits in peripheral vision. His affected sister and brother also were found to have
central field loss on visual field testing. Although retinal appearances were grossly normal, retinal visualization with ocular coherence tomography
(OCT) showed nerve fiber thinning to varying extents in the three affected siblings. (D) Sagittal T1 MRI study the brain of the female proband at
40 years of age showing mild cerebral and cerebellar volume loss. Subtle white matter signal abnormality in periventricular white matter was also
seen on T2/FLAIR sequences (not shown).
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symptoms during childhood, or hospitalizations. Brother
1 (III:12), developed hand incoordination and tremor
early in his fourth decade, and, later, gait impairment.
Examination demonstrated leg weakness with cognitive
impairment, cerebellar ataxia, and parkinsonian features
including mild rigidity, bradykinesia, masked facies, and
hypophonia. Gait showed reduced stride length and re-
duced arm swing bilaterally. Deep tendon reflexes were
symmetrically reduced. Similar to the proband, he had
learning disability and attention-deficit without hyper-
activity during childhood. A trial of levodopa-carbidopa
initially provided subjective benefit, but caused light-
headedness and was later discontinued. Examination did
not change. Selegiline reportedly improved the patient’s
activity levels and caused a subjective reduction in tre-
mor. Trihexyphenidyl resulted in subjective improve-
ments in rigidity, bradykinesia, and sialorrhea, although
physical examination remained essentially unchanged.
There was no graying of the hair. Funduscopy revealed
mild optic nerve pallor, right congenital hypertrophy of
retinal pigment epithelium and left choroidal nevus. Visual
acuity was normal, but contrast sensitivity was reduced.
Goldmann perimetry revealed central and peripheral loss
(Figure 2C).
Brother 2 (III:14) has residual voiding difficulties and
right lower extremity pain after having been diagnosed
with radiculopathy secondary to a spinal arteriovenous
malformation (AVM) aged 28 years. He developed bilat-
eral, symmetric, progressive leg weakness age 29, a year
after embolization of his AVM. He reported graying from
his teenage years. He developed upper extremity tremor,worse on the right side, at the age of 31. On most recent
physical evaluation, at age 33, he had brisk reflexes and
weakness in lower extremities, with normal neuro-
psychologic testing, generally scoring in the low average
to average range. Greatest neuropsychologic deficits were
in finger dexterity, confrontation naming, and executive
functioning. He had diffuse pigmentary abnormalities,
especially apparent on the limbs and back, and similar in
appearance to those seen in his brother and sister.
Funduscopy was normal, although contrast sensitivity was
mildly reduced. Goldmann perimetry revealed central loss.
He was given a trial of levodopa-carbidopa for parkinson-
ian symptoms, but did not tolerate it. Neither affected
brother had symptoms or signs suggestive of immunode-
ficiency or abnormal bleeding, although Brother 1 did ex-
hibit subclinical evidence of periodontitis.
Neuroimaging and neurophysiology
Serial MRI of the proband’s brain (performed at aged
37 years, 40 years, and 43 years) revealed global atrophy
(prominence of CSF spaces; volume loss of cerebellar
vermis), and diffuse, subtle increases in T2/FLAIR signal
intensity in periventricular white matter (Figure 2D) be-
coming more prominent over time. Brother 1 also had
mild global atrophy on MRI at 38 years with mild cere-
bellar volume loss and a similar subtle T2/FLAIR pattern
to his sister. Brother 2 presented with progressive para-
paresis 12 months after embolization of the spinal AVM,
at which time MRI failed to demonstrate progression or
expansion of the AVM; MRI brain at aged 33 years was
reported as normal. Electromyography (EMG) and nerve
conduction studies in the proband demonstrated re-
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left peroneal nerve F waves, consistent with subacute
axonal neuropathy, more severe in the lower limb.
Brother 1 had EMG changes consistent with a chronic
neurogenic process with apparent motor neuropathy,
worse distally. Brother 2 had no electrophysiologic evi-
dence of peripheral neuropathy with results suggestive
of polyradiculopathy.
Tissue sampling and immunologic studies
Skin biopsy on the proband demonstrated appearances
suggestive of amyloidosis cutis dyschromica (ACD) with
extensive deposition of amyloid which appeared to be of
keratinocytic origin (Figure 3A). All three affected siblings
had normal complete blood count indices, coagulation
studies, liver function, and lipid profiles. Peripheral smear
in all three siblings demonstrated abnormal polymorpho-
nuclear leukocytes with numerous enlarged, variably-sized
cytoplasmic granules (Figure 3B). The proband and both
brothers had pigmentary clumping evident on light micro-
copy of hair shafts. Fibrinogen levels at baseline were high
normal or mildly elevated, and ferritin levels were in the
low normal range. Natural killer cell function was absent
or very low (0.0–0.6 lytic units; normal >2.6) in all three
siblings. Quantitative IgG, IgA and IgM were within nor-
mal limits.
Genetic testing
Single nucleotide polymorphism (SNP) array on genomic
DNA from the proband did not show any significantly in-
creased regions of homozygosity. Sequencing of the entire
coding region of LYST identified homozygosity for a novel
six base pair in-frame deletion in exon 43 (c.9827_9832A
TACAA, Figure 4), predicting the loss of asparagine and
threonine residues from LYST (p.Asn3276_Thr3277del).Figure 3 (A) In a skin biopsy sample from the proband, keratinocytic
for high molecular weight cytokeratin, which showed extensive depo
The dermal deposits showed positivity with Congo red staining and apple
with polarization. Additionally, fissured amphophilic globules were observe
superficial reticular dermis (not shown). (B) Peripheral blood smear demon
cytoplasmic granules (Wright Giemsa, oil immersion).The proband was also homozygous for an intronic se-
quence variant (c.10701 + 8C>T) distal to the deletion.
Homozygosity for the same pathogenic deletion was con-
firmed in both clinically affected brothers. The parents
(II:3 and II:4) and both apparently unaffected brothers
(III:10 and III:16) were confirmed as heterozygotes for the
deletion. The two elder affected siblings’ apparently un-
affected partners (III:8 and III:13) are also undergoing tes-
ting given their status as first cousins of their spouses;
neither of the spouses, nor any of the three children of
these two couples has any clinical features of CHS.
Other studies
The proband had appearances suggestive of hepatic
steatosis on abdominal ultrasound; neither brother had
this finding. All three siblings had normal splenic and
renal appearances on abdominal ultrasound. Of interest,
both affected brothers had low levels of total testoster-
one (205 and 155 ng/dL respectively; normal 260–1080).
Discussion
We present three adult siblings as examples of a rare, at-
tenuated form of Chédiak-Higashi syndrome, manifesting
with progressive neurodegenerative disease and with mild
or subclinical immunologic abnormalities, and abnormal
pigmentation. Neurologic manifestations in this form of
CHS are variable, but frequently include peripheral neur-
opathy, cognitive decline, and features of spinocerebellar
degeneration with cerebral and cerebellar volume loss and
abnormal white matter appearances on MRI [4,7,8].
Dystonia has also been reported [9]. HLA-identical allo-
geneic bone marrow transplant (BMT) was reported as an
acceptable curative treatment for classic CHS almost
20 years ago [10]. Despite demonstrating efficacy in
treating the immunodeficiency component of the disease,origin of amyloid was demonstrated by immunohistochemistry
sition of amyloid in the papillary and superficial reticular dermis.
green birefringence was apparent in the expanded papillary dermis
d, containing scattered melanophages and extending into the
strating polymorphonuclear leukocytes with enlarged, variably-sized
Figure 4 Sequence chromatogram comparing wild type LYST sequence (top row) to sequence from proband, who was found to be
homozygous for a pathogenic deletion in exon 43 of LYST (c.9827_9832ATACAA, bottom row). Homozygosity for this deletion was also
confirmed in both clinically affected brothers. Both parents (II:3 and II:4) and both clinically unaffected brothers (III:10 and III:16) were confirmed as
heterozygotes for the deletion.
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at a similar age in BMT recipients with classical CHS phe-
notypes [11,12]. Our patients had learning difficulties,
attention-deficit behaviors and other neuropsychologic de-
ficits that may have significantly predated the onset of
frank neurologic symptoms. Classical CHS has also been
associated with learning difficulties in young children, and,
later, with progressive, diffuse white matter abnormalities
on MRI as well as neurologic decline and accelerated im-
mune deterioration [4,13,14].
LYST is a ubiquitously expressed gene whose protein
product is concerned with control of exocytosis and traf-
ficking from secretory lysosomes [3,5,15,16] and may be
critical to microtubular stability. Several distinct do-
mains within the LYST polypeptide appear to be critical
to protein-protein interactions and organization of pro-
tein complexes important to lysosome-related organelles
[17]. Cytoplasmic giant granules, seen in leucocytes, are
a hallmark of CHS, and are also seen in neuronal cells
and perineuronal tissue [3]. Enlargements of lysosome-
derived organelles are also characteristically observed
[18]. Consistent with our experience, other authors
[8,19] have reported that granules in patients with atten-
uated disease are enlarged, but not as dramatically as is
seen in classic forms of the disease; it is therefore con-
ceivable that the diagnosis may be missed by inexperi-
enced technologists. With regard to observed neurologic
deterioration with advancing age, clumped irregular mel-
anin granules have been observed in the substantia nigra
in human patients at autopsy [20,21]. Murine models of
CHS with homozygous missense mutations in LYST have
exhibited predominant neurologic phenotypes including
lower motor performance scores than controls, with ac-
cumulation of giant lysosomes in neuronal cells and
intracytoplasmic inclusions in Purkinje cells of the cere-
bellum and motor cortex [22]. At autopsy, adults with
CHS had neuronal degeneration involving the inferiorolivary nuclei and the cerebellar cortex, with an overall
distribution similar to late cortical cerebellar atrophy
(LCCA) and olivopontocerebellar atrophy (OPCA), but
without pontine involvement [20].
AA protein (reactive) amyloidosis is usually observed
in the setting of chronic infectious or inflammatory di-
sease. Systemic AA amyloidosis has been reported previ-
ously in the setting of CHS, both in humans [20] and in
animals [18]. The only previous human report described
a Japanese woman with classic CHS who suffered recu-
rrent pyogenic infections and albinism noted from
infancy, and had post-mortem evidence of amyloid de-
position in multiple tissues including the kidney, liver,
thyroid, and ovary, and pituitary and parotid glands.
Reactive gliosis was observed in the brain. The authors
speculated that recurrent infections had contributed to
the development of amyloidosis, and that amyloid de-
position would become an increasingly common obser-
vation in CHS patients with classic phenotypes as a
function of cumulative burden of recurrent, severe infec-
tion, especially as these patients survive into adolescence
and adulthood in greater numbers as is anticipated as
BMT protocols become more refined with improved ef-
ficacy and reduced toxicity [20]. Neutropenia, observed
chronically or intermittently, has been reported in CHS
[23], and the fact that our patients were not neutropenic
at the time of evaluation does not exclude historical epi-
sodes of neutropenia. However, in view of the fact that
our patients do not have any significant history of recur-
rent infection, but have skin biopsy appearances consist-
ent with amyloid deposition, we suggest that amyloidosis
may be a component of the pathophysiology of CHS that
is independent of the burden of recurrent infection.
It has been suggested that neurologic manifestations
result directly from defective LYST in neurons and glial
cells, or from lymphocytic tissue infiltration during the ac-
celerated phase of the disease. Acute CNS manifestations,
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are described in other inherited hemophagocytic disorders
(Griscelli syndrome, X-linked lymphoproliferative disease).
Each of these disorders is amenable to BMT [24], but
neurologic disease develops despite successful BMT. Like
CHS, Griscelli syndrome type 2 can cause pigmentary ab-
normalities with hair graying, as well as neurological di-
sease, and is an important differential diagnosis in this
setting. Expanding knowledge of the role of lymphocytic
CNS infiltration in causing neurodegenerative disease in
CHS may determine optimal timing of transplant in CHS
patients, given the fact that many patients, if not all, ap-
pear destined to develop debilitating neurodegenerative
disease over the longer term. In the United States, trans-
plant if routinely offered in advance of the accelerated
phase of classic disease. In a single-center review of the
use of hematopoietic stem cell transplantation (HSCT) in
Griscelli syndrome type 2 [25], many patients continued
to suffer major neurological deficits after HSCT, leading
the authors to suggest that transplanting these patients
prior to the accelerated phase could be beneficial. The
presence of neurodegenerative signs appearing in classi-
cal CHS patients many years after BMT suggests that
neurodegeneration may be related in part to defective
lysosomal trafficking and vacuolar dysfunction. More re-
cently, it has been shown in a murine model that various
pathophysiologic aspects of CHS might be directly
dependent on oxidative membrane damage [17]. Due to
the large size of neurons and their expansive plasma
membranes, these and other cell types may be especially
sensitive to the adverse effects of accumulation of oxida-
tively damaged cell membranes.
The in-frame nature of the novel LYST deletion, present
in the homozygous state in all of the affected siblings in
this family, may account for the comparatively mild, late-
onset phenotype in these individuals. The deletion is lo-
cated distally in LYST (exon 43 out of 51), and causes loss
of two amino acid residues in the BEACH domain of LYST,
but does not cause a frameshift/premature termination. To
our knowledge, only four other mutations, all missense,
have been definitively associated with attenuated pheno-
types. A previously reported patient with classic CHS [12]
was a compound heterozygote for single base pair deletion
(c.9893delT) in a similar region of the BEACH domain and
a more proximal nonsense mutation (c.1540C>T). The de-
letion caused a frameshift resulting in premature protein
truncation downstream (F3298fsX3304), and resulted in an
infantile-onset immunodeficiency and lymphoproliferative
histiocytosis phenotype. Homozygosity for the mutant al-
lele in our cases suggests the siblings’ parents share a com-
mon ancestor. Parents denied being directly related,
although both families originate from the same region of
Pakistan. CHS has not, to our knowledge, been previously
reported in Pakistani kindreds.Based on our experiences, and the available literature
[8,9,26], patients with this pattern of CHS might benefit,
at least in the short term, from L-dopa, selegiline, trihe-
xylphenidyl, biperiden, or amantadine. At diagnosis, pa-
tients require multidisciplinary input from a neurologist
with expertise in movement disorders, as well as a clinical
immunologist (even if historical clues suggesting immuno-
deficiency are absent), an ophthalmologist, a neurophysi-
ologist, and a neuroradiologist. Both affected brothers in
this family had below normal levels of testosterone but
had fathered children; the significance of this finding is
unclear and requires further study.
Conclusions
This family expands the phenotype of CHS, and provides
additional characterization of central nervous system dis-
ease in such patients. These patients have complex medical
needs and require carefully integrated multidisciplinary
care. The pathophysiology of this form of the condition is
likely to be related to a combination of factors including
microtubular instability, impaired lysosomal trafficking,
oxidative injury, and amyloid deposition. Variant CHS is
phenotypically heterogenous and should be considered
when young adults develop neurodegenerative disease in
association with pigmentary abnormalities. The disorder
can be easily screened for with characteristic findings on
peripheral blood smear and hair sampling, although these
may be less conspicuous than in classic CHS phenotypes.
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